April 29, 2011 -- Columbia University of New York City has licensed worldwide rights covering autoimmune IP to China Institute of Strategy and Management Lanmeng Investment Co., Ltd. The IP posits a model of how the immune system distinguishes between foreign antigens and antigens produced by the individual. The discovery opens new treatment pathways for autoimmune diseases. More details....
